Business
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets\nCompany shares to begin trading on Nasdaq under the trading symbol \"RNTX\" effective January 13, 2025\nAUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics (\"Rein\") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. (\"Aileron\") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to Rein Therapeutics, Inc. The new name, logo, website, and branding elements reflect the Company's mission to develop first-in-class treatments to rein in diseases. The Company's common stock will begin trading under the Nasdaq ticker symbol \"RNTX\" effective January 13, 2025. The CUSIP number for the Company's common stock is not affected by the name change. The Company also highlighted its recent clinical and corporate achievements and provided its key strategic objectives for 2025.\n\n \n \n \n \n \n \n\n \n\"Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases,\" said Brian Windsor, Ph.D., President and Chief Executive Officer. \"This new chapter for the Company underscores our focus on reining in fibrosis and advancing our pipeline of novel candidates. We look forward to the initiation of a Phase 2 clinical trial for our lead candidate, LTI-03, in the first half of this year, aiming to bring hope to those affected by idiopathic pulmonary fibrosis.\"\nRecent Clinical Achievements\nLTI-03, a Caveolin-1 related peptide:In November 2024, the Company announced positive topline data from Cohort 2 of the Phase 1b clinical trial evaluating the safety and tolerability of inhaled high dose LTI-03 (5 mg BID) and a set of exploratory biomarkers in patients with idiopathic pulmonary fibrosis (IPF). Four biomarkers showed statistical significance in the combined Cohort 1 and Cohort 2 dataset, and five demonstrated dose dependence with respect to low dose (2.5 mg BID) Cohort 1, indicative of active pharmacodynamics. High dose LTI-03 continued to exhibit a favorable safety profile.202...